Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The WA Department of Health has sent an urgent reminder to medical staff to make sure they’re giving patients the right RSV ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age ...

Go to source). In clinical trials, ENFLONSIA reduced serious RSV-related illnesses requiring medical attention by and lowered the risk of hospitalization due to RSV by more than 80%.

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants.

Additionally, the incidence rates of RSV-associated hospitalization through day 150 were found to be comparable between clesrovimab and palivizumab (1.3% [95% CI, 0.4-2.9] and 1.5% [95% CI, 0.5-3.2], ...

The monoclonal antibody reduced the incidence of RSV-associated medically attended lower respiratory infections that had at least one indicator of lower respiratory infection or severity by 60.5% ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. The US Food and Drug Administration ...

Key takeaways: The FDA approved the monoclonal antibody clesrovimab-cfor for preventing RSV disease in babies. Unlike nirsevimab, which has weight-based dosing, clesrovimab has a fixed dose.

Clesrovimab-cfor provides a fixed 105-mg dose, simplifying administration and offering five months of protection against RSV in infants. The CLEVER trial demonstrated a 60.5% reduction in RSV ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...